News
Prolastin-C released in Canada
Forbes.com
RESEARCH TRIANGLE PARK, ND—Talecris Biotherapeutics Holdings Corp. said Tuesday it launched Prolastin-C, an intravenous drug that treats a protein deficiency that can cause emphysema, in Canada.
Prolastin-C is a new and more concentrated version of Prolastin, a drug that has been on the market for more than 20 years. Prolastin-C was approved in the United States in 2009.
The products treat Alpha-1 Antitrypsin Deficiency, or Alpha-1, an inherited condition that is the most common cause of genetic liver disease in children, and genetic emphysema in adults.
